AllianceBernstein’s CRISPR Therapeutics CRSP Stock Holding History

AllianceBernstein’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.44M	Buy	114,337 +17,980	+19%	+$948K	﹤0.01%	1496
2026 Q1	$5.05M	Hold	96,357	–	–	﹤0.01%	1541
2025 Q4	$5.05M	Buy	96,357 +10,023	+12%	+$600K	﹤0.01%	1536
2025 Q3	$5.6M	Sell	86,334 -286	-0.3%	-$16.4K	﹤0.01%	1464
2025 Q2	$4.21M	Buy	+86,620	New	+$3.35M	﹤0.01%	1556
2021 Q3	–	Sell	-1,439	Closed	-$233K	–	3297
2021 Q2	$233K	Sell	1,439 -580	-29%	-$70.5K	﹤0.01%	3108
2021 Q1	$246K	Buy	2,019 +700	+53%	+$106K	﹤0.01%	2986
2020 Q4	$202K	Buy	+1,319	New	+$156K	﹤0.01%	2992
2019 Q1	–	Sell	-60,400	Closed	-$1.73M	–	3119
2018 Q4	$1.73M	Buy	+60,400	New	+$2.1M	﹤0.01%	1905

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AllianceBernstein's CRSP Position: Q2 2026 in Review

AllianceBernstein increased its CRISPR Therapeutics (CRSP) stake by 19% in Q2 2026, buying an estimated $948K and bringing the position to 114,337 shares worth $5.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1496.

AllianceBernstein first reported a position in CRSP in Q4 2018 and has held it in 9 quarters since. The position peaked at $5.6M in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

AllianceBernstein held 114,337 shares of CRISPR Therapeutics worth $5.44M as of Q2 2026.
AllianceBernstein bought 17,980 CRISPR Therapeutics shares in Q2 2026, an estimated $948K.
CRISPR Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1496 holding.
AllianceBernstein first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 9 quarters since.
AllianceBernstein's CRISPR Therapeutics position peaked at $5.6M in Q3 2025.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.